Drug Profile
Research programme: bacterial biofilm inhibitors - ProclaRx
Alternative Names: PCL 1402; PCL 1440; PCL 1550; PCL-1404; PCL-1406; PCL-1407Latest Information Update: 11 Feb 2019
Price :
$50
*
At a glance
- Originator Nationwide Children's Hospital; Ohio State University; University of Southern California
- Developer ProclaRx
- Class Antibodies; Vaccines
- Mechanism of Action Bacterial outer membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Infections; Otitis media; Sinusitis
Most Recent Events
- 07 Feb 2019 Applied Biomolecular Technologies has merged with Molecular Technologies Laboratories to form InfinixBio
- 28 Jan 2019 No recent reports of development identified for preclinical development in Infections in USA
- 28 Jan 2019 No recent reports of development identified for preclinical development in Otitis-media in USA